• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MR nanoparticle contrast targets angiogenic markers of atherosclerosis

Article

CONTEXT: As atherosclerotic plaque invades the arterial wall, it develops a network of tiny new blood vessels. The integrin avBeta3 is a marker for angiogenesis and therefore represents an attractive target for molecular imaging aimed at the early identification of vulnerable and inflamed plaque.

RESULTS: Investigators at Washington University School of Medicine in St. Louis developed a nanoparticle targeted against avBeta3-integrin by incorporating hundreds of tailor-made peptide-like particles into its lipid outer layer. Also linked to each nanoparticle were some 90,000 molecules of gadolinium DTPA to enable detection by MR.

Patrick M. Winter, Ph.D., and colleagues injected the nanoparticles intravenously into atherosclerotic, cholesterol-fed rabbits. Using a 1.5T clinical MR scanner and T1-weighted imaging, they detected increased angiogenesis throughout the wall of the abdominal aorta in rabbits injected with integrin-targeted paramagnetic nanoparticles. On average, signal intensity increased by 47% at two hours. For comparison, rabbits were also injected with nontargeted paramagnetic particles; signal enhancement averaged just 26%. Equally important, pretreatment of the rabbits with integrin-targeted nonparamagnetic nanoparticles reduced contrast enhancement by at least 50% through competitive blocking, thus demonstrating the specificity of the nanoparticle's integrin targeting.

IMAGE: MR contrast enhancement appears in the cholesterol-fed rabbits two hours after injection with avBeta3-integrin in renal artery (A), mid-aorta (B), and diaphragm (C). (Provided by P. Winter; reprinted with permission from Circulation 2003;108:227-2274.)

IMPLICATIONS: The use of this novel paramagnetic nanoparticle may enable physicians not only to identify arterial plaque through its angiogenic blood supply, but also to track the effectiveness of anti-atherosclerosis therapies.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.